BioCentury
ARTICLE | Clinical News

NeRRe hopes to advance cough candidate despite Phase II miss

June 7, 2019 11:36 PM UTC

While NeRRe's orvepitant missed the primary endpoint of the Phase IIb VOLCANO-2 trial, the company believes the trial's patient-reported outcomes support advancement of the refractory chronic cough therapy into Phase III testing.

On the trial's secondary endpoints, NeRRe Therapeutics Ltd. (Stevenage, U.K.) reported that orvepitant, a neurokinin 1 receptor (NK1R; TACR1) antagonist, led to improved Leicester Cough Questionnaire scores vs. placebo (p=0.009), and reduced cough severity and urge to cough as measured by the visual analog scale (p=0.034 and p=0.005, respectively). ...

BCIQ Company Profiles

NeRRe Therapeutics Ltd.